Medarex

The integration of Celgene Corp. ’s research, discovery, preclinical and early clinical development programs into Bristol-Myers Squibb Co. ’s R&D pipeline is almost complete, but the combined compan

The Japanese academic discoverer of the PD-1 protein and the company that co-developed a blockbuster drug based on his work continue to be embroiled in a spat over patent royalties, with the protracte

The proposed $74bn merger of Bristol-Myers Squibb Co. and Celgene Corp. would be the third-largest biopharmaceutical M&A deal if it goes through at the terms announced Jan. 3, and like other mega-

The proposed $74bn merger of Bristol-Myers Squibb Co. and Celgene Corp. would be the third-largest biopharmaceutical M&A deal if it goes through at the terms announced Jan. 3, and like other mega-